References
1. Baeten JM, Kahle E, Lingappa JR, Coombs RW, Delany-Moretlwe S,
Nakku-Joloba E, Mugo NR, Wald A, Corey L, Donnell D, Campbell MS,
Mullins JI, Celum C, Partners in Prevention HSVHIVTST. Genital HIV-1 RNA
predicts risk of heterosexual HIV-1 transmission. Sci Transl Med2011; 3 (77): 77ra29.
2. John GC, Nduati RW, Mbori-Ngacha DA, Richardson BA, Panteleeff D,
Mwatha A, Overbaugh J, Bwayo J, Ndinya-Achola JO, Kreiss JK. Correlates
of mother-to-child human immunodeficiency virus type 1 (HIV-1)
transmission: association with maternal plasma HIV-1 RNA load, genital
HIV-1 DNA shedding, and breast infections. J Infect Dis 2001;183 (2): 206-12.
3. Taylor S, Boffito M, Vernazza PL. Antiretroviral therapy to reduce
the sexual transmission of HIV. J HIV Ther 2003; 8 (3):
55-66.
4. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF,
Cohen MS, Kashuba AD. Penetration of tenofovir and emtricitabine in
mucosal tissues: implications for prevention of HIV-1 transmission.Sci Transl Med 2011; 3 (112): 112re4.
5. Nicol MR, Corbino JA, Cottrell ML. Pharmacology of Antiretrovirals in
the Female Genital Tract for HIV Prevention. J Clin Pharmacol2018; 58 (11): 1381-95.
6. Cottrell ML, Prince HM, Allmon A, Mollan KR, Hudgens MG, Sykes C,
White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Patterson KB,
Kashuba AD. Cervicovaginal and Rectal Fluid as a Surrogate Marker of
Antiretroviral Tissue Concentration: Implications for Clinical Trial
Design. J Acquir Immune Defic Syndr 2016; 72 (5):
498-506.
7. Bennetto-Hood C, Johnson VA, King JR, Hoesley CJ, Acosta EP. Novel
methodology for antiretroviral quantitation in the female genital tract.HIV Clin Trials 2009; 10 (3): 193-9.
8. Amara AB, Else LJ, Tjia J, Olagunju A, Puls RL, Khoo S, Back DJ. A
validated method for quantification of efavirenz in dried blood spots
using high-performance liquid chromatography-mass spectrometry.Ther Drug Monit 2015; 37 (2): 220-8.
9. Olagunju A, Bolaji OO, Amara A, Waitt C, Else L, Soyinka J, Adeagbo
B, Adejuyigbe E, Siccardi M, Back D, Owen A, Khoo S. Development,
validation and clinical application of a novel method for the
quantification of efavirenz in dried breast milk spots using LC-MS/MS.J Antimicrob Chemother 2015; 70 (2): 555-61.
10. FDA. Food and Drug Administration. Guidance for Industry.
Bioanalytical Method Validation 2018. Maryland: Food and Drug
Administration, US Department of Health and Human Services. Available
from: https://www.fda.gov/media/70858/download.
11. Olagunju A, Anweh D, Okafor O, Dickinson L, Richman D, Owen A,
Adejuyigbe E. Viral and antiretroviral dynamics in HIV mother-to-child
transmission fluids (VADICT) – Protocol and data analysis plan for a
cohort study [version 1; referees: awaiting peer review].Wellcome Open Res 2019; 4 (34).
12. Duwal S, Seeler D, Dickinson L, Khoo S, von Kleist M. The Utility of
Efavirenz-based Prophylaxis Against HIV Infection. A Systems
Pharmacological Analysis. Front Pharmacol 2019; 10 : 199.
13. Duwal S, Dickinson L, Khoo S, von Kleist M. Mechanistic framework
predicts drug-class specific utility of antiretrovirals for HIV
prophylaxis. Plos Comput Biol 2019; 15 (1): e1006740.
14. Kwara A, Delong A, Rezk N, Hogan J, Burtwell H, Chapman S, Moreira
CC, Kurpewski J, Ingersoll J, Caliendo AM, Kashuba A, Cu-Uvin S.
Antiretroviral drug concentrations and HIV RNA in the genital tract of
HIV-infected women receiving long-term highly active antiretroviral
therapy. Clin Infect Dis 2008; 46 (5): 719-25.
15. Min SS, Corbett AH, Rezk N, Cu-Uvin S, Fiscus SA, Petch L, Cohen MS,
Kashuba AD. Protease inhibitor and nonnucleoside reverse transcriptase
inhibitor concentrations in the genital tract of HIV-1-infected women.J Acquir Immune Defic Syndr 2004; 37 (5): 1577-80.
16. Usala SJ, Schumacher GF. Volumetric self-sampling of cervicovaginal
fluid: a new approach to ovulation timing. Fertil Steril 1983;39 (3): 304-9.
17. Dumond JB, Nicol MR, Kendrick RN, Garonzik SM, Patterson KB, Cohen
MS, Forrest A, Kashuba AD. Pharmacokinetic modelling of efavirenz,
atazanavir, lamivudine and tenofovir in the female genital tract of
HIV-infected pre-menopausal women. Clin Pharmacokinet 2012;51 (12): 809-22.
18. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of
antiretroviral drugs in anatomical sanctuary sites: the male and female
genital tract. Antivir Ther 2011; 16 (8): 1149-67.
19. Adams JL, Patterson KB, Prince HM, Sykes C, Greener BN, Dumond JB,
Kashuba AD. Single and multiple dose pharmacokinetics of dolutegravir in
the genital tract of HIV-negative women. Antivir Ther 2013;18 (8): 1005-13.
20. Le MP, Belarbi L, Chaix ML, Dulioust E, Mahjoub N, Salmon D, Viard
JP, Duvivier C, Peytavin G, Launay O, Ghosn J. Penetration and antiviral
efficacy of total and unbound maraviroc, raltegravir and rilpivirine in
both female and male genital fluids from HIV-positive patients receiving
regimens containing these antiretrovirals. J Antimicrob Chemother2017; 72 (11): 3167-71.
21. Van Niekerk N, Nuttall J, Zeiser S, Nel A. Population
pharmacokinetic modelling of dapivirine. AIDS Res Hum
Retroviruses 2014; 30 : A38–A39.
22. Yang K-H, Schwartz J, Sykes C, Doncel G, Kashuba A. Population
pharmacokinetic model of vaginal tenofovir 1% gel in the cervicovaginal
fluid. AIDS Res Hum Retroviruses 2014; 30 : A38–A38.
23. Katz DF, Yuan A, Gao Y. Vaginal drug distribution modeling.Adv Drug Deliv Rev 2015; 92 : 2-13.
24. Thompson CG, Sedykh A, Nicol MR, Muratov E, Fourches D, Tropsha A,
Kashuba AD. Short communication: cheminformatics analysis to identify
predictors of antiviral drug penetration into the female genital tract.AIDS Res Hum Retroviruses 2014; 30 (11): 1058-64.
25. Parsons TL, Emory JF, Seserko LA, Aung WS, Marzinke MA. Dual
quantification of dapivirine and maraviroc in cervicovaginal secretions
from ophthalmic tear strips and polyester-based swabs via liquid
chromatographic-tandem mass spectrometric (LC-MS/MS) analysis. J
Pharm Biomed Anal 2014; 98 : 407-16.